论文部分内容阅读
１９９３年８月至１９９４年８月，１２１例晚期恶性肿瘤患者接受淋巴因子诱导的细胞毒细胞（ＬＩＣＣ）治疗，其中４５例加用姑息放疗（剂量２０～６５Ｇｙ，平均４５．３Ｇｙ）。结果：ＣＲ＋ＰＲ＋ＭＲ率４８／１２１（３９．７％），大部分患者全身情况改善，癌性症状缓解或改善，生活质量提高，９例存活已超过２４月。疗前卡氏评分、肿瘤血供、是否加用放疗及ＬＩＣＣ疗程数是影响疗效的重要因素（Ｐ＜０．０５）。作者认为ＬＩＣＣ是晚期恶性肿瘤一种安全有效的过继免疫疗法，合并放射治疗可协同抗癌。
From August 1993 to August 1994, 121 patients with advanced malignant tumors received lymphokine-inducing cytotoxic cells (LICC), of which 45 were treated with palliative radiotherapy (dose 20-65 Gy, mean 45.3 Gy). Results: The rate of CR+PR+MR was 48/121 (39.7%). The general condition of most patients improved, the cancer symptoms were relieved or improved, and the quality of life improved. Nine cases survived for more than 24 months. Pre-treatment K-Score, tumor blood supply, plus radiotherapy and LICC treatment were important factors affecting the efficacy (P<0.05). The authors believe that LICC is a safe and effective adoptive immunotherapy for advanced malignant tumors, and combined radiation therapy can synergistically fight cancer.